Corient Private Wealth LLC Lowers Holdings in Agilent Technologies, Inc. $A

Corient Private Wealth LLC trimmed its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 3.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 185,108 shares of the medical research company’s stock after selling 6,313 shares during the period. Corient Private Wealth LLC owned about 0.07% of Agilent Technologies worth $21,845,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of A. Brighton Jones LLC increased its holdings in shares of Agilent Technologies by 6.1% during the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after purchasing an additional 270 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Agilent Technologies by 1.1% during the first quarter. Dimensional Fund Advisors LP now owns 1,162,783 shares of the medical research company’s stock valued at $136,012,000 after buying an additional 12,284 shares during the period. Cresset Asset Management LLC increased its holdings in Agilent Technologies by 10.5% in the first quarter. Cresset Asset Management LLC now owns 9,300 shares of the medical research company’s stock valued at $1,088,000 after buying an additional 884 shares in the last quarter. Raymond James Financial Inc. raised its position in shares of Agilent Technologies by 2.8% in the first quarter. Raymond James Financial Inc. now owns 368,661 shares of the medical research company’s stock worth $43,126,000 after acquiring an additional 10,077 shares during the period. Finally, Versor Investments LP acquired a new position in shares of Agilent Technologies in the first quarter worth about $364,000.

Insider Buying and Selling

In other Agilent Technologies news, VP Rodney Gonsalves sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $154.99, for a total value of $464,970.00. Following the transaction, the vice president directly owned 31,846 shares of the company’s stock, valued at $4,935,811.54. This trade represents a 8.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Padraig Mcdonnell sold 12,490 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total value of $1,873,500.00. Following the completion of the sale, the chief executive officer owned 33,448 shares of the company’s stock, valued at $5,017,200. This trade represents a 27.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 16,401 shares of company stock worth $2,468,962 over the last three months.

Agilent Technologies Stock Down 1.8%

NYSE A opened at $136.64 on Thursday. The business has a fifty day moving average price of $145.50 and a 200 day moving average price of $129.71. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.52 and a current ratio of 1.96. The company has a market cap of $38.74 billion, a P/E ratio of 29.90, a P/E/G ratio of 4.04 and a beta of 1.27. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $160.27.

Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.01. The company had revenue of $1.86 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.46 EPS. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. Research analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Investors of record on Tuesday, January 6th will be paid a dividend of $0.255 per share. The ex-dividend date of this dividend is Tuesday, January 6th. This represents a $1.02 annualized dividend and a yield of 0.7%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.25. Agilent Technologies’s dividend payout ratio is currently 21.66%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on A shares. Bank of America raised their target price on Agilent Technologies from $150.00 to $165.00 and gave the company a “neutral” rating in a research report on Tuesday, November 25th. Wells Fargo & Company raised their price objective on Agilent Technologies from $150.00 to $175.00 and gave the company an “overweight” rating in a report on Tuesday, November 25th. Citigroup boosted their price objective on Agilent Technologies from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Agilent Technologies in a research report on Monday. Finally, UBS Group lifted their price target on shares of Agilent Technologies from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $161.77.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.